<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can Respir J</journal-id><journal-id journal-id-type="iso-abbrev">Can. Respir. J</journal-id><journal-id journal-id-type="publisher-id">CRJ</journal-id><journal-title-group><journal-title>Canadian Respiratory Journal</journal-title></journal-title-group><issn pub-type="ppub">1198-2241</issn><issn pub-type="epub">1916-7245</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7479474</article-id><article-id pub-id-type="pmid">32934758</article-id><article-id pub-id-type="doi">10.1155/2020/1401053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Crisan-Dabija</surname><given-names>Radu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Grigorescu</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pavel</surname><given-names>Cristina-Alice</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Artene</surname><given-names>Bogdan</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0597-8839</contrib-id><name><surname>Popa</surname><given-names>Iolanda Valentina</given-names></name><email>iolivp@gmail.com</email><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cernomaz</surname><given-names>Andrei</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3424-1588</contrib-id><name><surname>Burlacu</surname><given-names>Alexandru</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>University of Medicine and Pharmacy &#x0201c;Grigore T. Popa&#x0201d; Ia&#x00219;i, Pulmonology Department, Head of Clinic of Pulmonary Diseases, Iasi, Romania</aff><aff id="I2">
<sup>2</sup>University of Medicine and Pharmacy &#x0201c;Grigore T. Popa&#x0201d; Ia&#x00219;i, Department Thoracic Surgery, Clinic of Thoracic Surgery Ia&#x00219;i, Hospital of Pulmonary Diseases Iasi, Iasi, Romania</aff><aff id="I3">
<sup>3</sup>Clinic of Pulmonary Diseases, Iasi, Romania</aff><aff id="I4">
<sup>4</sup>Department of Interventional Cardiology-Cardiovascular Diseases Institute, Iasi, Romania</aff><aff id="I5">
<sup>5</sup>Institute of Gastroenterology and Hepatology, Ia&#x00219;i, Romania</aff><aff id="I6">
<sup>6</sup>&#x0201c;Grigore T. Popa&#x0201d; University of Medicine, Iasi, Romania</aff><aff id="I7">
<sup>7</sup>University of Medicine and Pharmacy &#x0201c;Grigore T. Popa&#x0201d; Ia&#x00219;i, Pulmonology Department, Institute of Oncology, Ia&#x00219;i, Romania</aff><author-notes><fn fn-type="other"><p>Academic Editor: Jack Kastelik</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>9</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>1401053</elocation-id><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>29</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Radu Crisan-Dabija et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p> The threat of contagious infectious diseases is constantly evolving as demographic explosion, travel globalization, and changes in human lifestyle increase the risk of spreading pathogens, leading to accelerated changes in disease landscape. Of particular interest is the aftermath of superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as tuberculosis (TB), which remains a significant disease for public health worldwide and especially in emerging economies. </p></sec><sec><title>Methods and Results</title><p> The PubMed electronic database was systematically searched for relevant articles linking TB, influenza, and SARS-CoV viruses and subsequently assessed eligibility according to inclusion criteria. Using a data mining approach, we also queried the COVID-19 Open Research Dataset (CORD-19). We aimed to answer the following questions: What can be learned from other coronavirus outbreaks (focusing on TB patients)? Is coinfection (TB and SARS-CoV-2) more severe? Is there a vaccine for SARS-CoV-2? How does the TB vaccine affect COVID-19? How does one diagnosis affect the other? <italic>Discussions</italic>. Few essential elements about TB and SARS-CoV coinfections were discussed. First, lessons from past outbreaks (other coronaviruses) and influenza pandemic/seasonal outbreaks have taught the importance of infection control to avoid the severe impact on TB patients. Second, although challenging due to data scarcity, investigating the pathological pathways linking TB and SARS-CoV-2 leads to the idea that their coexistence might yield a more severe clinical evolution. Finally, we addressed the issues of vaccination and diagnostic reliability in the context of coinfection. </p></sec><sec><title>Conclusions</title><p> Because viral respiratory infections and TB impede the host's immune responses, it can be assumed that their lethal synergism may contribute to more severe clinical evolution. Despite the rapidly growing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with latent TB and TB sequelae still lies ahead. The trial is registered with <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206">NCT04327206</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01829490">NCT01829490</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206">NCT04121494</ext-link>.</p></sec></abstract><funding-group><award-group><funding-source>Romanian Academy of MedAcademy of Medical Sciences</funding-source></award-group><award-group><funding-source>European Regional Development Fund</funding-source><award-id>MySMIS 107124</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The global threat of contagious infectious diseases, particularly tuberculosis (TB), has long concerned authorities in charge of public health policies. Most data and all predictions concerning global epidemiology of TB are based on &#x0201c;<italic>real-life</italic>&#x0201d; analysis (surveys and national surveillance programs) conducted by the World Health Organization (WHO) [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. The incidence of TB is slowly declining but remains a significant issue worldwide (ranked as the ninth leading cause of death worldwide and the leading cause of a single infectious agent [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]), especially in most middle-income and emerging-economy countries.</p><p>TB remains of great significance for the public health in Eastern Europe (e.g., Romania), which has the highest TB incidence in the European Union (EU) (4 times higher than the average), accounting for a quarter of the TB burden in the EU [<xref rid="B4" ref-type="bibr">4</xref>]. The incidence of TB increased in Romania after 1990, peaking in 2002 (142.2%), with a downward trend since then, 54.5/100 000 in 2016, and 54.2% lower than in 2002 [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. A series of factors augmented the severity of TB endemic in Romania, namely, a large number of severe forms, cases with multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB), HIV coinfection, and (TB-related) mortality in children. TB mortality in Romania has followed the same course as the incidence, with a peak in 2002 and an elevation of XDR-TB cases between 2012 and 2015, with a threefold increase [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Influenza infection may promote the progression of latent <italic>Mycobacterium tuberculosis</italic> (MTB) infection to active TB, alter the clinical presentation of TB, and also possibly exacerbate pulmonary TB (PTB) [<xref rid="B6" ref-type="bibr">6</xref>]. Both influenza and tuberculosis hinder host immune responses. Specifically, influenza can impair T-cell immunity and weaken innate immune responses against secondary bacterial infections [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>].</p><p>This deleterious synergism of viral and bacterial infections increases the risk of influenza-associated mortality, and patients with PTB may increase the severity of influenza disease and death due to chronic lung disease and immunosuppression. Epidemiologic data suggest an increased rate of influenza or severe influenza-associated disease in patients with TB during influenza pandemics [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>] or during seasonal influenza epidemics [<xref rid="B10" ref-type="bibr">10</xref>] compared with non-TB individuals.</p></sec><sec id="sec2"><title>2. Objectives</title><p>Individuals with chronic respiratory infections, including TB, are first to experience the adverse effects of a pneumotropic pandemic, especially in the healthcare setting [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Given that both coronavirus disease 2019 (COVID-19) and TB become important causes of mortality worldwide [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B12" ref-type="bibr">12</xref>] and the TB endemic situation in Romania [<xref rid="B4" ref-type="bibr">4</xref>], we sought to explore the possible outcomes of the inevitable collide of the two pandemics. Considering SARS-CoV-2 high transmissibility, it is very likely that COVID-19 will be of particular concern for individuals infected with MTB [<xref rid="B13" ref-type="bibr">13</xref>]. Also, coinfection with MTB is of particular importance as the TB diagnosis might be missed or shadowed by concern about COVID-19.</p><p>Therefore, we aimed to review the available literature in order to<list list-type="alpha-lower"><list-item><p>predict the impact of COVID-19 pandemic on patients with latent TB and TB sequelae based on the data available from the past influenza pandemic and seasonal influenza outbreaks (considering similar or more severe outcomes in the current pandemic)</p></list-item><list-item><p>underline possible clinical particularities and diagnostic errors on these patients</p></list-item><list-item><p>evaluate possible different therapeutic approaches on TB patients (latent, sequelae, or active) given that current COVID-19 treatment may induce mycobacterial proliferation [<xref rid="B14" ref-type="bibr">14</xref>]</p></list-item></list></p></sec><sec id="sec3"><title>3. Methods</title><p>The electronic database of PubMed was systematically searched for relevant articles from the inception until March 2020. The search terms used were [&#x0201c;<italic>tuberculosis</italic>&#x0201d; OR &#x0201c;TB&#x0201d;], AND [&#x0201c;<italic>flu</italic>&#x0201d; OR &#x0201c;<italic>influenza</italic>&#x0201d;], AND [&#x0201c;<italic>SARS</italic>&#x0201d; OR &#x0201c;<italic>SARS-CoV</italic>&#x0201d; OR &#x0201c;<italic>SARS-CoV-1</italic>&#x0201d;], AND <italic>MERS-CoV</italic>. The search process included article identification, removing the duplicates, screening titles and abstracts, and assessing eligibility of the selected full texts. Additionally, reference lists of valid articles were checked for studies of relevance. Articles were included if they involved data about past TB, SARS-CoV-1, MERS-CoV epidemics, TB-influenza viruses, and TB-SARS-CoV-1 coinfections or clinical or laboratory research on the immune responses during coinfections. Journal articles published with full text or abstracts in English were eligible for inclusion.</p><p>In order to identify emerging coinfection particularities of novel coronavirus SARS-CoV-1, we queried the COVID-19 Open Research Dataset (CORD-19), the current largest open dataset available with over 47000 scholarly articles, including over 36000 with full text about COVID-19, SARS-CoV-2, and other coronaviruses. The CORD-19 dataset is available at <ext-link ext-link-type="uri" xlink:href="https://pages.semanticscholar.org/coronavirus-research">https://pages.semanticscholar.org/coronavirus-research</ext-link>. Given the large quantity of textual data in CORD-19, we applied a data mining approach to answer a few questions: (1) What can one learn from other coronaviruses epidemics (with a focus on TB patients)? (2) Is coinfection (TB and SARS-CoV-2) more severe? (3) Is there a vaccine for SARS-CoV-2? How does the TB vaccine influence COVID-19? (4) How does one condition influence the diagnosis of the other one?</p><p>Articles were exported from CORD-19 and merged locally for further processing. Articles of interest were retrieved by administering the query &#x0201c;COVID&#x0201d; OR &#x0201c;COVID-19&#x0201d; OR &#x0201c;2019-nCoV&#x0201d; OR &#x0201c;SARS-CoV-2&#x0201d; OR &#x0201c;Novel coronavirus&#x0201d; OR &#x0201c;Tuberculosis&#x0201d; OR &#x0201c;<italic>Mycobacterium tuberculosis</italic>&#x0201d; OR &#x0201c;Flu&#x0201d; OR &#x0201c;Influenza&#x0201d; OR &#x0201c;Coinfection&#x0201d; OR &#x0201c;Vaccine&#x0201d; OR &#x0201c;Immunization.&#x0201d; Data mining was further applied to select only articles that met our topics of interest about coinfections between particular pathogens stated earlier and COVID-19 developing vaccines. The study selection process and number of papers identified in each phase are illustrated in the flowchart (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="sec4"><title>4. Discussions</title><sec id="sec4.1"><title>4.1. What Can One Learn from Other Past Epidemics/Pandemics?</title><p>For a better understanding of managing a novel coronavirus pandemic, one needs to understand the experience. Since the first discovery of coronaviruses in 1960, there have been described three human coronaviruses known to cause fatal respiratory diseases:<list list-type="alpha-lower"><list-item><p>The severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV, now known as SARS-CoV-1) that led to a global epidemic in 2002 [<xref rid="B13" ref-type="bibr">13</xref>]</p></list-item><list-item><p>The Middle-East respiratory syndrome coronavirus (MERS-CoV) which was discovered in 2012 and still affects people from 27 countries [<xref rid="B15" ref-type="bibr">15</xref>]</p></list-item><list-item><p>Most recently, the novel coronavirus (SARS-CoV-2), whose outbreak led to an ongoing pandemic with thousands of new cases being confirmed each day and a growing number of reported deaths worldwide [<xref rid="B13" ref-type="bibr">13</xref>] (<xref ref-type="fig" rid="fig2">Figure 2</xref>)</p></list-item></list></p><p>It has to be added that while SARS-CoV-1 was associated in 37 countries with 8096 cases and 774 deaths during the entire nine months of the epidemic [<xref rid="B13" ref-type="bibr">13</xref>] and MERS with only 2494 cases and 858 deaths in 27 countries [<xref rid="B13" ref-type="bibr">13</xref>], SARS-CoV-2 spread (and still spreading) in 208 countries with 1009625 confirmed COVID-19 cases and 51737 confirmed deaths (as of the 3rd of April 2020) in only three months since the first declared case of COVID-19 pneumonia [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Its high transmissibility rate reminds of the 1918-19 influenza pandemic when it has been estimated that almost a third of the world's population is affected with a mortality rate of 2.5% [<xref rid="B9" ref-type="bibr">9</xref>]. Other significant differences between influenza pandemics and current novel coronavirus pandemic can be found. One of the most notable is that death was less frequent amidst healthcare workers in influenza pandemics as it was the case in SARS, MERS, and now COVID-19 pandemic [<xref rid="B17" ref-type="bibr">17</xref>]. Despite this, other similarities still exist between SARS-CoV-2 and influenza as the striking resemblance of pathological features documented in COVID-19 associated acute respiratory distress syndrome (ARDS) and H7N9-induced ARDS [<xref rid="B18" ref-type="bibr">18</xref>]. Also, it has been suggested that influenza viruses, as well as SARS-CoV-2, significantly upregulate angiotensin-converting enzyme 2 (ACE2) receptors. This upregulation facilitates novel coronavirus entrance into the host cell and makes patients infected by influenza more susceptible to SARS-CoV-2.</p><p>Some studies have shown that, in a patient with TB, induction of type I interferons (IFNs) determined by influenza infection could be detrimental [<xref rid="B11" ref-type="bibr">11</xref>], impeding the immune-competent host's ability to limit bacterial replication. Thus it promotes the infection [<xref rid="B19" ref-type="bibr">19</xref>] and precipitates TB mortality rate (pneumonia and influenza death rates among the age group most affected by TB exceeded in 1918 the TB mortality rate noted before and after the pandemic) [<xref rid="B9" ref-type="bibr">9</xref>]. Higher TB death rates were noted in winter months (coinciding with seasonal influenza outbreaks), which led to the suggestion of PTB being an independent risk factor for influenza-associated mortality [<xref rid="B10" ref-type="bibr">10</xref>]. In contrast, few studies suggested no association between influenza coinfection and PTB's progression or severity [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. One murine model demonstrated that although influenza infection increased the IFN-<italic>&#x003b3;</italic> secretion, it had little effect on bacterial load in chronically infected mice with BCG [<xref rid="B21" ref-type="bibr">21</xref>]. Half of the analytical studies included in a recent systematic review showed no evidence on influenza affecting PTB presentation or its outcomes or, conversely, PTB affecting influenza presentation and outcomes [<xref rid="B6" ref-type="bibr">6</xref>]. Nevertheless, the magnitude of TB burden in a given setting might be an essential factor that should be considered in any study regarding PTB because its results might be biased [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>During the 2002-03 SARS-CoV-1 epidemic, it was highlighted that to contain the epidemic, the correct management of symptomatic patients (within and outside the hospital) was critical [<xref rid="B22" ref-type="bibr">22</xref>]. The secondary transmission within Vancouver (Canada) was stopped due to the correct management of several imported cases, as opposed to other places (e.g., Toronto, Canada, or Taipei, Taiwan) where the incorrect management conducted to spread further and hospital clusters [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. Also, inappropriate implementation of infection control strategies in Singapore led to massive healthcare personnel infection (half of the SARS cases were among healthcare workers) and several superspreading events [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>TB in SARS patients has been reported in several studies from TB endemic countries such as Singapore, China, or Taiwan [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>], all with known TB patients that acquired SARS and in individuals that developed TB after recovery from SARS [<xref rid="B25" ref-type="bibr">25</xref>]. The transient immunosuppression characterized both conditions [<xref rid="B26" ref-type="bibr">26</xref>], a reason for poorer IgG antibody response and a delayed viral clearance in coinfected SARS patients [<xref rid="B24" ref-type="bibr">24</xref>]. Also, the use of corticoid therapy in SARS added even more on immunosuppression [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>During an epidemic, many measures are taken (especially in hospitals) to limit the transmission of the disease to na&#x000ef;ve patients. However, overcrowding hospitals are prone to mistakes. Known-TB patients from China supposedly acquired SARS due to exposure to SARS patients from the same hospital wards. Hence, coinfection could have been avoided [<xref rid="B24" ref-type="bibr">24</xref>]. Even though most of them recovered without complications, SARS coinfection on TB cases led to significantly lower mean CD4+ and CD8&#x02009;+&#x02009;T cells and undetectable or unusually low antibody levels after SARS recovery [<xref rid="B24" ref-type="bibr">24</xref>]. Also, the viral excretion was two times longer in sputum and five times longer in stools for TB&#x02009;+&#x02009;SARS patients compared to SARS patients without TB, which translates into a higher potential to spread the virus [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>When dealing with a possible SARS patient from an endemic TB region, one should never forget TB as a coexisting pathology. In April 2003, a SARS-related hospital screening from Taipei (Taiwan) resulted in discovering 60&#x02009;TB cases among healthcare workers [<xref rid="B27" ref-type="bibr">27</xref>]. Moreover, during the SARS-CoV-1 epidemic from Singapore, SARS cases were reported developing active PTB short after recovering from SARS [<xref rid="B25" ref-type="bibr">25</xref>], data compatible with previous studies on mice regarding the suppression of cellular immunity after a viral infection [<xref rid="B11" ref-type="bibr">11</xref>]. There is also data on MERS-CoV augmenting TB by the added immunosuppression and reinforcing the need to evaluate a suspected patient [<xref rid="B28" ref-type="bibr">28</xref>].</p><sec id="sec4.1.1"><title>4.1.1. Key Points</title><p>
<list list-type="order"><list-item><p>Influenza pandemic/seasonal outbreaks and other coronaviruses epidemics might have a negative impact on TB patients.</p></list-item><list-item><p>Transmission prevention was crucial for containing the epidemics.</p></list-item><list-item><p>In order to decrease the opportunity of SARS-CoV-2 spreading among TB cases, hospital treatment for TB patients should be limited to severe cases.</p></list-item></list>
</p></sec></sec><sec id="sec4.2"><title>4.2. Is Coinfection More Severe? Pathological Pathways Linking TB and SARS-CoV-2</title><p>Although the pathophysiology of SARS-CoV-2 is not fully understood, it seems most likely similar to the one of SARS-CoV-1. Substantial evidence suggests that SARS-CoV-2 infection could initiate an aggressive inflammation by increasing cytokines secretion such as interleukin-1<italic>&#x003b2;</italic> (IL-1<italic>&#x003b2;</italic>), interferon-<italic>&#x003b3;</italic> (IFN-<italic>&#x003b3;</italic>), tumor necrosis factor-<italic>&#x003b1;</italic> (TNF-<italic>&#x003b1;</italic>), interleukin-2 (IL-2), interleukin-4 (IL-4), and interleukin-10 (IL-10), their plasma levels being associated with disease severity, leading to a so-called &#x0201c;<italic>cytokine storm</italic>,&#x0201d; thus explaining some young adults' disease severity [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>Immune system hyperreaction was also described in the 1918&#x02013;1919 influenza pandemic, which was the first known pandemic to report an excess risk of death among individuals 25&#x02013;35 years old [<xref rid="B9" ref-type="bibr">9</xref>]. Although cytokines storms seem to be induced by both SARS-CoV-2 and influenza, given the early stage in our understanding regarding SARS-CoV-2 infection, to conclude that the immunomodulatory or immune suppressive effects of these two viruses are highly similar might be premature, few studies proved that influenza aggravated the pulmonary status of individuals with TB so that latent TB could become active, a closed cavity might open, and various lesions might progress, leading to further deterioration of pulmonary function [<xref rid="B9" ref-type="bibr">9</xref>]. In this regard, a mouse coronavirus model demonstrated the ability to reactivate dormant MTB from CD271&#x02009;+&#x02009;mesenchymal stem cells through the altruistic stem cell-based defense mechanism, predicting a potential increase of TB in SARS-CoV-2 era. Additionally, in a cohort of 49 patients with active TB and COVID-19, the diagnosis of COVID-19 preceded or was simultaneous (within seven days) with TB in 23 patients, raising the suspicion that SARS-CoV-2 infection might boost the development of active TB. However, this remains purely speculative as individuals with latent TB infection were not followed up over time [<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Cytokines have an essential role in host resistance to TB infection, being first demonstrated in murine infection models [<xref rid="B19" ref-type="bibr">19</xref>] and later validated by severe mycobacterial disease findings in patients with mutations in the IFN-<italic>&#x003b3;</italic> and IL-12 signaling pathways and rheumatoid arthritis or Crohn's disease patients treated with TNF-<italic>&#x003b1;</italic> blockade [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B31" ref-type="bibr">31</xref>].</p><p>Since the SARS-CoV-2 is a newly discovered pathogen (first infection being reported in December 2019) [<xref rid="B29" ref-type="bibr">29</xref>], little data about the coinfection with MTB could be found (especially considering the long incubation period of MTB from exposure to developing the disease, often with a slow onset) [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Still, the existent studies showed that TB status might play a role in the development of severe acute respiratory syndrome in SARS-CoV-2 coinfection, considering the cases described in China and India [<xref rid="B34" ref-type="bibr">34</xref>]. A recent meta-analysis [<xref rid="B35" ref-type="bibr">35</xref>] concluded that patients with TB are not more likely to get COVID-19, but TB is associated with a 2.1-fold increased risk of severe COVID-19 disease, although the statistical difference was not significant. Moreover, no increased risk for mortality in coincident COVID-19 and TB was found. However, this study included a small number of TB patients infected with SARS-CoV-2, and the publication bias was not rigorously assessed. Thus, the findings should be interpreted with caution. Similarly, in a cohort of 69 patients, in all cases, COVID-19 contributed to worsen the prognosis of TB patients and/or cause death, although TB was not a significant determinant of mortality [<xref rid="B36" ref-type="bibr">36</xref>].</p><p>On the contrary, 20 patients with TB and COVID-19 had a rather benign clinical course of the coinfection, with only one patient that died. TB lesions at chest X-ray were not aggravated, and only four patients had signs of newly developed pneumonia [<xref rid="B37" ref-type="bibr">37</xref>].</p><p>One should keep in mind that the existence of underlying conditions, autoimmune diseases, poor hygiene, and overcrowding is all known as risk factors for developing one, another, or both diseases [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. In a paper developing a model of pathogen dissemination in the outpatient clinic, it was suggested that populations with a high risk of contracting influenza or SARS might also have a higher prevalence of MTB [<xref rid="B38" ref-type="bibr">38</xref>]. It is no coincidence that the regions with the highest TB burden, as reported by the World Health Organization, were predicted to be hardest hit by the social and economic consequences of COVID-19 [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>Another serious problem posed by the COVID-19 pandemic is the treatment continuity of TB patients. The nature of the disease, with extended treatment regimens and poor outcomes with drug resistance resulting from therapy discontinuation, are significant problems even in regular times, all the more in a pandemic context with numerous and stringent isolation measures [<xref rid="B40" ref-type="bibr">40</xref>]. This shifts the directly observed therapy to self-administered therapy, for which digital-health technologies such as electronic medication monitors and video-supported therapy were recommended to ensure adherence to treatments [<xref rid="B41" ref-type="bibr">41</xref>]. Discontinuation risks and other challenges faced by the tuberculosis clinical trials in the face of COVID-19 have been discussed, sounding the alarm around these threats [<xref rid="B42" ref-type="bibr">42</xref>].</p><sec id="sec4.2.1"><title>4.2.1. Key Points</title><p>
<list list-type="order"><list-item><p>Cytokines seem to play an essential role in both COVID-19 and TB, their plasma level being associated with disease's severity.</p></list-item><list-item><p>Immune system hyperreaction could explain a more unfortunate outcome in people 25&#x02013;35 years old.</p></list-item><list-item><p>Although there is limited data on MTB and COVID-19 coinfection, one could reasonably presume that their coexistence might have a more severe evolution for the patient.</p></list-item></list>
</p></sec></sec><sec id="sec4.3"><title>4.3. (Proven or Presumed) Clinical and Paraclinical Impacts of Vaccination</title><p>One of the most effective ways to prevent diseases caused by pathogens, like bacteria or viruses, proved to be vaccination [<xref rid="B43" ref-type="bibr">43</xref>]. Since the first discovery of SARS, extensive research was done to find a vaccine to prevent the disease [<xref rid="B44" ref-type="bibr">44</xref>]. Different vaccine types were tested: inactivated or live-attenuated virus, DNA-based vaccines, recombinant proteins, virus-like particles, and viral vectors with some promising efficiency, but with neither being finally approved for use [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>]. Recent data suggest that the SARS-CoV-2 genome is up to 80% similar to SARS-CoV-1 and up to 50% similar to MERS-CoV [<xref rid="B46" ref-type="bibr">46</xref>], so previous studies on protective immune responses SARS-CoV-1 or MERS-CoV may aid vaccine development for SARS-CoV-2 [<xref rid="B47" ref-type="bibr">47</xref>]. Considering that there is no approved vaccine neither for SARS-CoV-1 nor for MERS-CoV, other options are considered, such as the vaccine used for TB prevention [<xref rid="B48" ref-type="bibr">48</xref>].</p><p>Since 1921 a vaccine is used widely for TB prevention, a live-attenuated strain of the bovine tubercle bacillus named bacillus Calmette&#x02013;Guerin (BCG) [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>]. In 1927, it was observed that BCG-vaccinated newborns had a three times lower mortality rate in their first year of life than the unvaccinated ones [<xref rid="B51" ref-type="bibr">51</xref>]. Later was noted a decrease in infectious morbidities, protecting both mice (against secondary fungal or parasitic infections with <italic>Candida albicans</italic> or <italic>Schistosoma mansoni</italic> through tissue macrophages activation) [<xref rid="B49" ref-type="bibr">49</xref>] and infants (against acute lower respiratory infections). Thus, the risk of acute lower respiratory infections in BCG-vaccinated infants seemed to be 37% lower than in unvaccinated controls among children &#x0003c;5 years old [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B52" ref-type="bibr">52</xref>]. However, there seem to be no proven data regarding the duration of these beneficial effects [<xref rid="B53" ref-type="bibr">53</xref>], and there is data suggesting that subsequent administration of different vaccines was associated with altering the nonspecific immunity [<xref rid="B54" ref-type="bibr">54</xref>], so one might safely presume that the chance of a BCG vaccine received decades ago in childhood could influence the course of one pandemic in adulthood which would be low.</p><p>Although one might argue that the lack of widespread BCG vaccination in the United States may be influencing the course of their pandemic compared to countries with broad spread vaccination, one should also keep in mind that the United States delayed the implementation of infection control strategies (that could avoid superspreading events). There still is a reluctance of face masks wearing when out in public, a measure that has been proven to slow and stop the spread of the virus [<xref rid="B55" ref-type="bibr">55</xref>].</p><p>There is data suggesting that BCG vaccination of adults could increase the capacity of producing proinflammatory cytokines such as Il-1<italic>&#x003b2;</italic> and IL-6, which leads to nonspecific protection against unrelated pathogens like <italic>Staphylococcus aureus</italic> or <italic>Candida albicans</italic> [<xref rid="B56" ref-type="bibr">56</xref>].</p><p>Considering these facts, the BCG vaccine is contemplated as a potential candidate against respiratory viruses [<xref rid="B48" ref-type="bibr">48</xref>]. Moreover, Muldron Children's Research Institute from Australia already announced a phase III randomized controlled trial, which will determine if healthcare workers' BCG vaccination will have any impact on SARS-CoV-2 infection (BCG Vaccination to Protect Healthcare Workers against COVID-19, BRACE, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206">NCT04327206</ext-link>). However, more time is needed to establish its supposed efficiency.</p><p>Given the high TB burden, especially in emerging economies and the high global threat of SARS-CoV-2, a vaccine that may be beneficial in combating TB and COVID-19 would be of high interest.</p><p>Adenoviral vectors have previously been used to improve immunogenicity with excellent results in the enhancement of both humoral and cellular immunity [<xref rid="B57" ref-type="bibr">57</xref>]. ChAdOx1 85A has been contemplated as a TB vaccine first in healthy vaccinated BCG adults (Phase I Trial to Evaluate the Safety and Immunogenicity of a ChAdOx1 85A Vaccination with and without MVA85A Boost in Healthy BCG Vaccinated Adults, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01829490">NCT01829490</ext-link>) and most recently with an ongoing trial in healthy adults with or without prior BCG vaccination (A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206">NCT04121494</ext-link>).</p><p>The University of Oxford appears to be repurposing this viral-based TB vaccine for use against SARS-CoV-2 by changing the immunogenetic antigen expressed. ChAdOx1 nCoV-19 (more recently known as AZD1222) is a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein. In rhesus macaques, ChAdOx1 nCoV-19 induced both humoral and cellular immune responses after one single dose. In humans, the preliminary results demonstrated an acceptable safety profile and spike-specific T cell responses as early as day 7, peaking on day 14, and maintained up to day 56 [<xref rid="B57" ref-type="bibr">57</xref>]. The neutralizing antibody responses were observed in up to 91% of the cases after one single dose and up to 100% after a booster dose [<xref rid="B19" ref-type="bibr">19</xref>]. 10560 healthy UK volunteers are expected to be enrolled in a phase II/III clinical trial that already begun and they will undergo follow-up for one-year after enrollment (A Phase 2/3 Study to Determine the Efficacy, Safety, and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206">NCT04327206</ext-link>).</p><p>It is noted that SARS-CoV-2 envelope spike (S) protein has a decisive role for determining host tropism and transmission capacity [<xref rid="B46" ref-type="bibr">46</xref>] and T cell epitopes-based peptide derived from S proteins that map to SARS-CoV-2 proteins [<xref rid="B47" ref-type="bibr">47</xref>] and subunit vaccines based on S protein are also considered for preventing SARS-CoV-2 infection [<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>].</p><p>Novel methods are emerging such as reverse vaccinology that refers to the process of constructing vaccines by detecting viral antigens through genomic analysis using bioinformatics tools. Reverse vaccinology has successfully been applied to fight against the Zika virus or Chikungunya virus. One study proposed reverse vaccinology and immunoinformatics methods to design potential subunit vaccines against SARS-CoV-2 using the highly antigenic viral proteins and epitopes. Suggested vaccine constructs appeared to confer good immunogenic response through various computational studies. Three vaccine constructs were designed, and the best one was selected through molecular docking study. Another study proposes a specific synthetic vaccine epitope and peptidomimetic agent, identified through bioinformatics methods [<xref rid="B60" ref-type="bibr">60</xref>].</p><p>Currently, there are 15 potential vaccine candidates for SARS-CoV-2 in the pipeline globally developed using various technologies (messenger RNA, synthetic DNA, synthetic, and modified virus-like particles) [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>].</p><sec id="sec4.3.1"><title>4.3.1. Key Points</title><p>
<list list-type="order"><list-item><p>SARS-CoV-2 genome is up to 80% similar to SARS-CoV-1 and 50% similar to MERS-CoV.</p></list-item><list-item><p>No SARS vaccine was approved for clinical use (in 18 years of research).</p></list-item><list-item><p>Ongoing trials on the SARS-CoV-2 vaccine are on the highest interest.</p></list-item></list>
</p></sec></sec><sec id="sec4.4"><title>4.4. Diagnostic Errors in the Context of COVID-19 and TB Coexistence (or How Does One Condition Influence the Diagnosis of the Other?)</title><p>TB and COVID-19 are mainly respiratory diseases that primarily affect the lungs; however, the onset of TB is often slow compared to COVID-19, which seems to develop in a few days from exposure [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. Given the clinical and imagistic similarities such as cough, fever, or shortness of breath and various radiological pulmonary lesions [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B22" ref-type="bibr">22</xref>], accurate diagnostic tests should be made available to avoid overlooking one condition in favor of the other one.</p><p>Tuberculin skin test (TST) and with a greater sensibility and specificity, the interferon-gamma release assays (IGRAs) are widely used for TB screening [<xref rid="B63" ref-type="bibr">63</xref>]. Given their results are influenced by the host's immune response after MTB (or BCG) exposure [<xref rid="B64" ref-type="bibr">64</xref>], there is a gap for diagnostic errors in individuals with an impaired immune system, such as in a concurrent severe infection [<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>]. Increased age, low peripheral lymphocyte count, high body mass index, and immunosuppressive therapies were also associated with false-negative results [<xref rid="B66" ref-type="bibr">66</xref>] that could lead to missing TB diagnose. Moreover, an excess of inflammatory markers could affect IGRAs sensitivity, and the high value of C-reactive protein (CRP) might be a confounder for false-negative results [<xref rid="B67" ref-type="bibr">67</xref>].</p><p>It has been observed that high CRP and low peripheral lymphocyte counts could occur within a few days of exposure to SARS-CoV-2 [<xref rid="B68" ref-type="bibr">68</xref>]. Therefore, this observation may lead to the possibility that a patient with latent TB or TB sequel may have a false-negative IGRA.</p><p>As SARS-CoV-2 has not been identified for a few months in humans, there is no specific treatment [<xref rid="B13" ref-type="bibr">13</xref>]. Given the growing number of reported cases, suspected patients must be diagnosed as quickly as possible to isolate and limit further transmission [<xref rid="B13" ref-type="bibr">13</xref>]. Conventional methods such as assays for detecting viral antigens or antiviral antibodies and newer methods of diagnosis as multiplex nucleic acid amplification have been developed and used clinically [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>With the urge of identifying the radiological features of SARS-CoV-2 infection, with the community transmission present in most countries, and with its nonspecific clinical onset (fever, dry cough, dyspnoea and radiological findings of bilateral infiltrates, and even pleural effusion and cavitation) [<xref rid="B69" ref-type="bibr">69</xref>], doctors may either be facing a steep differential diagnostic or not consider tuberculosis at all.</p><p>Considering the sudden onset of the SARS-CoV-2 pandemic, countries struggled to quickly find a possible treatment to prevent respiratory failures and deaths, especially among patients with respiratory comorbidities. Also, since its fatal dynamics, there is no time to carry out new drug development in the traditional manner. Therefore, screening for already available drugs (for any activity against SARS-CoV-2) [<xref rid="B13" ref-type="bibr">13</xref>] is usually preferred in the first instance. It seems that an antiviral used for HIV infection, composed of two protease inhibitors (lopinavir and ritonavir), would have a therapeutic effect on coronavirus infections. It seems to have entered as a recommendation in the treatment of the COVID-19 in a short time [<xref rid="B13" ref-type="bibr">13</xref>]. Other compounds, such as redexivir, favivir, ribavirin, nitrazine, and chloroquine/hydroxychloroquine, are evaluated [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B68" ref-type="bibr">68</xref>]. Chloroquine and hydroxychloroquine have been shown to shorten the duration of SARS-CoV-2 viremia by reducing the viral load [<xref rid="B68" ref-type="bibr">68</xref>]. However, hydroxychloroquine has also been associated with a higher risk of nontuberculous mycobacterial (NTM) infection in rheumatoid arthritis patients [<xref rid="B14" ref-type="bibr">14</xref>].</p><sec id="sec4.4.1"><title>4.4.1. Key Points</title><p>
<list list-type="order"><list-item><p>Coinfection of TB and SARS-CoV-2 may be challenging to diagnose.</p></list-item><list-item><p>SARS-CoV-2 infection may mask the clinical and radiological active TB.</p></list-item><list-item><p>Patients receiving the proposed treatment for COVID-19 may be at risk for the infection with NTM.</p></list-item></list>
</p></sec></sec></sec><sec id="sec5"><title>5. Conclusions</title><p>Because viral respiratory infections and TB impede the host's immune responses, their lethal synergism can be assumed to contribute to more severe clinical evolution. Coinfection most likely affects both sides of these patients: rapid development of severe acute respiratory syndrome through cytokine-mediated immune response and increased risk of tuberculosis reactivation. As a lesson from previous outbreaks, hospital treatment for patients with tuberculosis should be limited to severe cases, to prevent the spread of SARS-CoV-2 in TB cases. Despite the rapidly increasing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with latent TB and TB sequelae and to guide management in this particular context still lies ahead.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was funded by the Romanian Academy of MedAcademy of Medical Sciences and European Regional Development Fund (MySMIS 107124: Funding Contract 2/Axa 1/31.07.2017/107124 SMIS).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>Data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec><title>Disclosure</title><p>Cristina Grigorescu has the same contribution as the first author.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this article.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zignol</surname><given-names>M.</given-names></name><name><surname>van Gemert</surname><given-names>W.</given-names></name><name><surname>Falzon</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007&#x02013;2010</article-title><source><italic toggle="yes">Bulletin of the World Health Organization</italic></source><year>2012</year><volume>90</volume><issue>2</issue><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.2471/blt.11.092585</pub-id><pub-id pub-id-type="pmid">22423162</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coker</surname><given-names>R. J.</given-names></name></person-group><article-title>Review: multidrug-resistant tuberculosis: public health challenges</article-title><source><italic toggle="yes">Tropical Medicine and International Health</italic></source><year>2004</year><volume>9</volume><issue>1</issue><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3156.2003.01156.x</pub-id><pub-id pub-id-type="other">2-s2.0-0842287120</pub-id><pub-id pub-id-type="pmid">14728604</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beaut&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Dara</surname><given-names>M.</given-names></name><name><surname>Colombani</surname><given-names>P.</given-names></name><name><surname>Ehsani</surname><given-names>S.</given-names></name><name><surname>Gozalov</surname><given-names>O.</given-names></name><name><surname>Hovanesyan</surname><given-names>A.</given-names></name></person-group><source><italic toggle="yes">Tuberculosis Surveillance and Monitoring in Europe 2017</italic></source><year>2017</year><volume>150</volume><publisher-loc>Stockholm, Sweden</publisher-loc><publisher-name>European Centre for Disease Prevention and Control</publisher-name></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golli</surname><given-names>A.-L.</given-names></name><name><surname>Ni&#x00163;u</surname><given-names>M. F.</given-names></name><name><surname>Turcu</surname><given-names>F.</given-names></name><name><surname>Popescu</surname><given-names>M.</given-names></name><name><surname>Ciobanu-Mitrache</surname><given-names>L.</given-names></name><name><surname>Olteanu</surname><given-names>M.</given-names></name></person-group><article-title>Tuberculosis remains a public health problem in Romania</article-title><source><italic toggle="yes">The International Journal of Tuberculosis and Lung Disease</italic></source><year>2019</year><volume>23</volume><issue>2</issue><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.5588/ijtld.18.0270</pub-id><pub-id pub-id-type="other">2-s2.0-85065439333</pub-id><pub-id pub-id-type="pmid">30808456</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni&#x00162;u</surname><given-names>F. M.</given-names></name><name><surname>Olteanu</surname><given-names>M.</given-names></name><name><surname>Streba</surname><given-names>C. T</given-names></name><etal/></person-group><article-title>Tuberculosis and its particularities in Romania and worldwide</article-title><source><italic toggle="yes">Romanian journal of morphology and embryology=Revue roumaine de morphologie et embryologie</italic></source><year>2017</year><volume>58</volume><issue>2</issue><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">28730222</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walaza</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Tempia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Influenza and tuberculosis co-infection: a systematic review</article-title><source><italic toggle="yes">Influenza and Other Respiratory Viruses</italic></source><year>2020</year><volume>14</volume><issue>1</issue><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/irv.12670</pub-id><pub-id pub-id-type="other">2-s2.0-85073948431</pub-id><pub-id pub-id-type="pmid">31568678</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>C.-L.</given-names></name><name><surname>Shaler</surname><given-names>C. R.</given-names></name><name><surname>McCormick</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2010</year><volume>184</volume><issue>4</issue><fpage>2048</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902772</pub-id><pub-id pub-id-type="other">2-s2.0-77949910622</pub-id><pub-id pub-id-type="pmid">20083661</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noymer</surname><given-names>A.</given-names></name></person-group><article-title>The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: an age, period, cohort analysis</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2011</year><volume>29</volume><issue>2</issue><fpage>B38</fpage><lpage>B41</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.02.053</pub-id><pub-id pub-id-type="other">2-s2.0-79960177946</pub-id><pub-id pub-id-type="pmid">21757102</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oei</surname><given-names>W.</given-names></name><name><surname>Nishiura</surname><given-names>H.</given-names></name></person-group><article-title>The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918-19</article-title><source><italic toggle="yes">Computational and Mathematical Methods in Medicine</italic></source><year>2012</year><volume>2012</volume><pub-id pub-id-type="publisher-id">124861</pub-id><pub-id pub-id-type="doi">10.1155/2012/124861</pub-id><pub-id pub-id-type="other">2-s2.0-84864913582</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walaza</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Nanoo</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>A. L.</given-names></name><name><surname>McAnerney</surname><given-names>J.</given-names></name><name><surname>von Mollendorf</surname><given-names>C.</given-names></name></person-group><article-title>Excess mortality associated with influenza among tuberculosis deaths in South Africa, 1999&#x02013;2009</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2015</year><volume>10</volume><issue>6</issue><pub-id pub-id-type="publisher-id">e0129173</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0129173</pub-id><pub-id pub-id-type="other">2-s2.0-84945954349</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redford</surname><given-names>P. S.</given-names></name><name><surname>Mayer-Barber</surname><given-names>K. D.</given-names></name><name><surname>McNab</surname><given-names>F. W.</given-names></name><etal/></person-group><article-title>Influenza A virus impairs control of <italic>Mycobacterium tuberculosis</italic> coinfection through a type I interferon receptor-dependent pathway</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2014</year><volume>209</volume><issue>2</issue><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit424</pub-id><pub-id pub-id-type="other">2-s2.0-84890098871</pub-id><pub-id pub-id-type="pmid">23935205</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Organisation</surname><given-names>W. H.</given-names></name></person-group><source><italic toggle="yes">WHO Information on Tuberculosis and Pandemic Influenza A (H1N1)</italic></source><year>2009</year><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>WHO</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www9.who.int/tb/features_archive/h1n1/en/">http://www9.who.int/tb/features_archive/h1n1/en/</ext-link></comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.-Y.</given-names></name><name><surname>You</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2020</year><volume>22</volume><issue>2</issue><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2020.02.002</pub-id><pub-id pub-id-type="pmid">32087334</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brode</surname><given-names>S. K.</given-names></name><name><surname>Jamieson</surname><given-names>F. B.</given-names></name><name><surname>Ng</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Increased risk of mycobacterial infections associated with anti-rheumatic medications</article-title><source><italic toggle="yes">Thorax</italic></source><year>2015</year><volume>70</volume><issue>7</issue><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2014-206470</pub-id><pub-id pub-id-type="other">2-s2.0-84939232128</pub-id><pub-id pub-id-type="pmid">25911222</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Organization</surname><given-names>W. H.</given-names></name></person-group><article-title>MERS situation update</article-title><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html">http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html</ext-link></comment></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Organization</surname><given-names>W. H.</given-names></name></person-group><article-title>Coronavirus disease (COVID-19) pandemic</article-title><year>2019</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></comment></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rello</surname><given-names>J.</given-names></name><name><surname>Tejada</surname><given-names>S.</given-names></name><name><surname>Userovici</surname><given-names>C.</given-names></name><name><surname>Arvaniti</surname><given-names>K.</given-names></name><name><surname>Pugin</surname><given-names>J.</given-names></name><name><surname>Waterer</surname><given-names>G.</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19): a critical care perspective beyond China</article-title><source><italic toggle="yes">Anaesthia, Critical Care &#x00026; Pain Medicine</italic></source><year>2020</year><volume>39</volume><issue>3</issue><fpage>167</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.accpm.2020.03.001</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><source><italic toggle="yes">Clinical Study of Mesenchymal Stem Cell Treating Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection, a Hint for COVID-19 Treatment</italic></source><year>2020</year><publisher-loc>Beijing, China</publisher-loc><publisher-name>Engineering</publisher-name></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>K. D.</given-names></name><name><surname>Sher</surname><given-names>A.</given-names></name></person-group><article-title>Cytokine and lipid mediator networks in tuberculosis</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2015</year><volume>264</volume><issue>1</issue><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/imr.12249</pub-id><pub-id pub-id-type="other">2-s2.0-84923172430</pub-id><pub-id pub-id-type="pmid">25703565</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>S.</given-names></name><name><surname>Whitehead</surname><given-names>S.</given-names></name><name><surname>Thamthitiwat</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Concurrent influenza virus infection and tuberculosis in patients hospitalized with respiratory illness in Thailand</article-title><source><italic toggle="yes">Influenza and Other Respiratory Viruses</italic></source><year>2013</year><volume>7</volume><issue>3</issue><fpage>244</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2012.00413.x</pub-id><pub-id pub-id-type="other">2-s2.0-84876464374</pub-id><pub-id pub-id-type="pmid">22817684</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Co</surname><given-names>D. O.</given-names></name><name><surname>Hogan</surname><given-names>L. H.</given-names></name><name><surname>Karman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Interactions between T cells responding to concurrent mycobacterial and influenza infections</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2006</year><volume>177</volume><issue>12</issue><fpage>8456</fpage><lpage>8465</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.12.8456</pub-id><pub-id pub-id-type="other">2-s2.0-33845443748</pub-id><pub-id pub-id-type="pmid">17142743</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Locatelli</surname><given-names>F.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Coronavirus infections: epidemiological, clinical and immunological features and hypotheses</article-title><source><italic toggle="yes">Cell Stress</italic></source><year>2020</year><volume>4</volume><issue>4</issue><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.15698/cst2020.04.216</pub-id><pub-id pub-id-type="pmid">32292881</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D. S. C.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome</article-title><source><italic toggle="yes">Infectious Disease Clinics of North America</italic></source><year>2019</year><volume>33</volume><issue>4</issue><fpage>869</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2019.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-85073828407</pub-id><pub-id pub-id-type="pmid">31668196</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Arnaud</surname><given-names>F.</given-names></name><name><surname>Pan-He</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Zhong-Tao</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>T.</given-names></name></person-group><article-title>Pulmonary tuberculosis and SARS, China</article-title><source><italic toggle="yes">Emerging Infectious Disease Journal</italic></source><year>2006</year><volume>12</volume><issue>4</issue><fpage>p. 707</fpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>J. G. H.</given-names></name><name><surname>Lee</surname><given-names>C. C.</given-names></name><name><surname>Leo</surname><given-names>Y. S.</given-names></name><name><surname>Guek-Hong Low</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>C.-C.</given-names></name><name><surname>Leo</surname><given-names>Y.-S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome and pulmonary tuberculosis</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2004</year><volume>38</volume><issue>12</issue><fpage>e123</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1086/421396</pub-id><pub-id pub-id-type="pmid">15227635</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Qiu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2004</year><volume>189</volume><issue>4</issue><fpage>648</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1086/381535</pub-id><pub-id pub-id-type="other">2-s2.0-10744231501</pub-id><pub-id pub-id-type="pmid">14767818</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><article-title>Nosocomial transmission of <italic>Mycobacterium tuberculosis</italic> found through screening for severe acute respiratory syndrome&#x02014;Taipei, Taiwan, 2003</article-title><source><italic toggle="yes">MMWR Morbidity and Mortality Weekly Report</italic></source><year>2004</year><volume>53</volume><issue>15</issue><fpage>321</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">15103296</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfaraj</surname><given-names>S. H.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name><surname>Altuwaijri</surname><given-names>T. A.</given-names></name><name><surname>Memish</surname><given-names>Z. A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for infection control</article-title><source><italic toggle="yes">Intervirology</italic></source><year>2017</year><volume>60</volume><issue>1-2</issue><fpage>53</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000477908</pub-id><pub-id pub-id-type="other">2-s2.0-85021951091</pub-id><pub-id pub-id-type="pmid">28683463</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W. J.</given-names></name><name><surname>Ni</surname><given-names>Z. Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W. H.</given-names></name><name><surname>Ou</surname><given-names>C. Q.</given-names></name><name><surname>He</surname><given-names>J. X.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadolini</surname><given-names>M.</given-names></name><name><surname>Codecasa</surname><given-names>L. R.</given-names></name><name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>J.-M.</given-names></name><etal/></person-group><article-title>Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases</article-title><source><italic toggle="yes">European Respiratory Journal</italic></source><year>2020</year><volume>56</volume><issue>1</issue><pub-id pub-id-type="publisher-id">2001398</pub-id><pub-id pub-id-type="doi">10.1183/13993003.01398-2020</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>J.</given-names></name><name><surname>Keane</surname><given-names>J.</given-names></name></person-group><article-title>How tumour necrosis factor blockers interfere with tuberculosis immunity</article-title><source><italic toggle="yes">Clinical and Experimental Immunology</italic></source><year>2010</year><volume>161</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20491796</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Organization</surname><given-names>W. H.</given-names></name></person-group><source><italic toggle="yes">Addressing the Needs of Vulnerable Populations</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/tb/areas-of-work/population-groups/en/">https://www.who.int/tb/areas-of-work/population-groups/en/</ext-link></comment></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K.</given-names></name><name><surname>Gumbo</surname><given-names>T.</given-names></name><name><surname>Gandhi</surname><given-names>N. R.</given-names></name><etal/></person-group><article-title>Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis</article-title><source><italic toggle="yes">The Lancet Respiratory Medicine</italic></source><year>2014</year><volume>2</volume><issue>4</issue><fpage>321</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/s2213-2600(14)70031-1</pub-id><pub-id pub-id-type="other">2-s2.0-84897963303</pub-id><pub-id pub-id-type="pmid">24717628</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasri</surname><given-names>S.</given-names></name><name><surname>Wiwanitkit</surname><given-names>V.</given-names></name></person-group><article-title>Tuberculosis and novel Wuhan coronavirus infection: pathological interrelationship</article-title><source><italic toggle="yes">Indian Journal of Tuberculosis</italic></source><year>2020</year><volume>67</volume><issue>2</issue><fpage>p. 264</fpage><pub-id pub-id-type="doi">10.1016/j.ijtb.2020.02.004</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name></person-group><article-title>Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.26311</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>I.</given-names></name><name><surname>Centis</surname><given-names>R.</given-names></name><name><surname>D&#x02019;Ambrosio</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts</article-title><source><italic toggle="yes">Pulmonology</italic></source><year>2020</year><volume>26</volume><issue>4</issue><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.pulmoe.2020.05.002</pub-id><pub-id pub-id-type="pmid">32411943</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stochino</surname><given-names>C.</given-names></name><name><surname>Villa</surname><given-names>S.</given-names></name><name><surname>Zucchi</surname><given-names>P.</given-names></name><name><surname>Parravicini</surname><given-names>P.</given-names></name><name><surname>Gori</surname><given-names>A.</given-names></name><name><surname>Raviglione</surname><given-names>M. C.</given-names></name></person-group><article-title>Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital</article-title><source><italic toggle="yes">European Respiratory Journal</italic></source><year>2020</year><volume>56</volume><issue>1</issue><pub-id pub-id-type="publisher-id">2001708</pub-id><pub-id pub-id-type="doi">10.1183/13993003.01708-2020</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>R. H.</given-names></name><name><surname>David</surname><given-names>G. S.</given-names></name><name><surname>Philip</surname><given-names>S. C.</given-names></name></person-group><article-title>Pathogen transmission and clinic scheduling</article-title><source><italic toggle="yes">Emerging Infectious Disease Journal</italic></source><year>2006</year><volume>12</volume><issue>1</issue><fpage>p. 159</fpage></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>E.</given-names></name></person-group><article-title>WHO global progress report on tuberculosis elimination</article-title><source><italic toggle="yes">The Lancet Respiratory Medicine</italic></source><year>2020</year><volume>8</volume><issue>1</issue><fpage>p. 19</fpage><pub-id pub-id-type="doi">10.1016/s2213-2600(19)30418-7</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amimo</surname><given-names>F.</given-names></name><name><surname>Lambert</surname><given-names>B.</given-names></name><name><surname>Magit</surname><given-names>A.</given-names></name></person-group><article-title>What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?</article-title><source><italic toggle="yes">Tropical Medicine and Health</italic></source><year>2020</year><volume>48</volume><issue>1</issue><fpage>p. 32</fpage><pub-id pub-id-type="doi">10.1186/s41182-020-00219-6</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manyazewal</surname><given-names>T.</given-names></name><name><surname>Woldeamanuel</surname><given-names>Y.</given-names></name><name><surname>Blumberg</surname><given-names>H. M.</given-names></name><name><surname>Fekadu</surname><given-names>A.</given-names></name><name><surname>Marconi</surname><given-names>V. C.</given-names></name></person-group><article-title>The fight to end tuberculosis must not be forgotten in the COVID-19 outbreak</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2020</year><volume>26</volume><issue>6</issue><fpage>811</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0917-1</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusen</surname><given-names>I. D.</given-names></name></person-group><article-title>Challenges in tuberculosis clinical trials in the face of the COVID-19 pandemic: a sponsor&#x02019;s perspective</article-title><source><italic toggle="yes">Tropical Medicine and Infectious Disease</italic></source><year>2020</year><volume>5</volume><issue>2</issue><fpage>p. 86</fpage><pub-id pub-id-type="doi">10.3390/tropicalmed5020086</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Organisation</surname><given-names>W. H.</given-names></name></person-group><source><italic toggle="yes">Coronavirus Disease (COVID-19) Pandemic</italic></source><year>2019</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/topics/vaccines/en/">https://www.who.int/topics/vaccines/en/</ext-link></comment></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Donaldson</surname><given-names>E. F.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name></person-group><article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2013</year><volume>11</volume><issue>12</issue><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3143</pub-id><pub-id pub-id-type="other">2-s2.0-84888011629</pub-id><pub-id pub-id-type="pmid">24217413</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Current advancements and potential strategies in the development of MERS-CoV vaccines</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2014</year><volume>13</volume><issue>6</issue><fpage>761</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.912134</pub-id><pub-id pub-id-type="other">2-s2.0-84901003129</pub-id><pub-id pub-id-type="pmid">24766432</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)30251-8</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S. F.</given-names></name><name><surname>Quadeer</surname><given-names>A. A.</given-names></name><name><surname>McKay</surname><given-names>M. R.</given-names></name></person-group><article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title><source><italic toggle="yes">Viruses</italic></source><year>2020</year><volume>12</volume><issue>3</issue><pub-id pub-id-type="doi">10.3390/v12030254</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>J. A.</given-names></name><name><surname>G&#x000e1;lvez</surname><given-names>N. M. S.</given-names></name><name><surname>Rivera</surname><given-names>C. A.</given-names></name><name><surname>Palavecino</surname><given-names>C. E.</given-names></name><name><surname>C&#x000e9;spedes</surname><given-names>P. F.</given-names></name><name><surname>Rey-Jurado</surname><given-names>E.</given-names></name></person-group><article-title>Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2018</year><volume>9</volume><issue>2875</issue><pub-id pub-id-type="doi">10.3389/fimmu.2018.02875</pub-id><pub-id pub-id-type="other">2-s2.0-85058918185</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelidou</surname><given-names>A.</given-names></name><name><surname>Diray-Arce</surname><given-names>J.</given-names></name><name><surname>Conti</surname><given-names>M. G.</given-names></name><name><surname>Smolen</surname><given-names>K. K.</given-names></name><name><surname>van Haren</surname><given-names>S. D.</given-names></name><name><surname>Dowling</surname><given-names>D. J.</given-names></name></person-group><article-title>BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2020</year><volume>11</volume><issue>332</issue><pub-id pub-id-type="doi">10.3389/fmicb.2020.00332</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>P.</given-names></name><name><surname>Doherty</surname><given-names>T. M.</given-names></name></person-group><article-title>The success and failure of BCG - implications for a novel tuberculosis vaccine</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2005</year><volume>3</volume><issue>8</issue><fpage>656</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1211</pub-id><pub-id pub-id-type="other">2-s2.0-22944433876</pub-id><pub-id pub-id-type="pmid">16012514</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P.</given-names></name><name><surname>Benn</surname><given-names>C. S.</given-names></name></person-group><article-title>Saving lives by training innate immunity with bacille Calmette-Guerin vaccine</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2012</year><volume>109</volume><issue>43</issue><fpage>17317</fpage><lpage>17318</lpage><pub-id pub-id-type="doi">10.1073/pnas.1215761109</pub-id><pub-id pub-id-type="other">2-s2.0-84867919836</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollm-Delgado</surname><given-names>M.-G.</given-names></name><name><surname>Stuart</surname><given-names>E. A.</given-names></name><name><surname>Black</surname><given-names>R. E.</given-names></name></person-group><article-title>Acute lower respiratory infection among Bacille Calmette-Gu&#x000e9;rin (BCG)-vaccinated children</article-title><source><italic toggle="yes">Pediatrics</italic></source><year>2014</year><volume>133</volume><issue>1</issue><fpage>e73</fpage><lpage>e81</lpage><pub-id pub-id-type="doi">10.1542/peds.2013-2218</pub-id><pub-id pub-id-type="other">2-s2.0-84891793379</pub-id><pub-id pub-id-type="pmid">24379224</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>A. J.</given-names></name><name><surname>Finn</surname><given-names>A.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Non-specific effects of vaccines: plausible and potentially important, but implications uncertain</article-title><source><italic toggle="yes">Archives of Disease in Childhood</italic></source><year>2017</year><volume>102</volume><issue>11</issue><fpage>1077</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2015-310282</pub-id><pub-id pub-id-type="other">2-s2.0-85024860995</pub-id><pub-id pub-id-type="pmid">28501809</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>N.</given-names></name><name><surname>Sparrow</surname><given-names>A.</given-names></name><name><surname>Ghebreyesus</surname><given-names>T. A.</given-names></name><name><surname>Netea</surname><given-names>M. G.</given-names></name></person-group><article-title>Considering BCG vaccination to reduce the impact of COVID-19</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2020</year><volume>395</volume><issue>10236</issue><fpage>1545</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31025-4</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>D. K.</given-names></name><name><surname>Akl</surname><given-names>E. A.</given-names></name><name><surname>Duda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2020</year><volume>395</volume><issue>10242</issue><fpage>1973</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31142-9</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covi&#x000e1;n</surname><given-names>C.</given-names></name><name><surname>Fern&#x000e1;ndez-Fierro</surname><given-names>A.</given-names></name><name><surname>Retamal-D&#x000ed;az</surname><given-names>A.</given-names></name><name><surname>D&#x000ed;az</surname><given-names>F. E.</given-names></name><name><surname>Vasquez</surname><given-names>A. E.</given-names></name><name><surname>Lay</surname><given-names>M. K.</given-names></name></person-group><article-title>BCG-induced cross-protection and development of trained immunity: implication for vaccine design</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2019</year><volume>10</volume><issue>2806</issue><pub-id pub-id-type="doi">10.3389/fimmu.2019.02806</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folegatti</surname><given-names>P. M.</given-names></name><name><surname>Ewer</surname><given-names>K. J.</given-names></name><name><surname>Aley</surname><given-names>P. K.</given-names></name><name><surname>Angus</surname><given-names>B.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2020</year><volume>369</volume><issue>10249</issue><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2020</year><volume>11</volume><issue>298</issue><pub-id pub-id-type="doi">10.3389/fmicb.2020.00298</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuate</surname><given-names>S.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Doerr</surname><given-names>H. W.</given-names></name><name><surname>&#x000dc;berla</surname><given-names>K.</given-names></name></person-group><article-title>Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies</article-title><source><italic toggle="yes">Virology</italic></source><year>2007</year><volume>362</volume><issue>1</issue><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.12.011</pub-id><pub-id pub-id-type="other">2-s2.0-34247243255</pub-id><pub-id pub-id-type="pmid">17258782</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>B.</given-names></name></person-group><article-title>Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus</article-title><source><italic toggle="yes">Computers in Biology and Medicine</italic></source><year>2020</year><volume>119</volume><pub-id pub-id-type="publisher-id">103670</pub-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2020.103670</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>M. X.</given-names></name><name><surname>Ang</surname><given-names>I. Y. H.</given-names></name><etal/></person-group><article-title>Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-ncoV): a systematic review</article-title><source><italic toggle="yes">Journal of Clinical Medicine</italic></source><year>2020</year><volume>9</volume><issue>3</issue><fpage>p. 623</fpage><pub-id pub-id-type="doi">10.3390/jcm9030623</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>K. K.</given-names></name><name><surname>Makia</surname><given-names>D.</given-names></name><name><surname>Maier</surname><given-names>R.</given-names></name><name><surname>Ludewig</surname><given-names>B.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name></person-group><article-title>Towards a coronavirus-based HIV multigene vaccine</article-title><source><italic toggle="yes">Clinical &#x00026; Developmental Immunology</italic></source><year>2006</year><volume>13</volume><issue>2&#x02013;4</issue><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1080/17402520600579168</pub-id><pub-id pub-id-type="other">2-s2.0-33845653452</pub-id><pub-id pub-id-type="pmid">17162377</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>The risk factor of false-negative and false-positive for T-SPOT.TB in active tuberculosis</article-title><source><italic toggle="yes">Journal of Clinical Laboratory Analysis</italic></source><year>2018</year><volume>32</volume><issue>2</issue><pub-id pub-id-type="publisher-id">e22273</pub-id><pub-id pub-id-type="doi">10.1002/jcla.22273</pub-id><pub-id pub-id-type="other">2-s2.0-85020275163</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L. L.</given-names></name><name><surname>Smith</surname><given-names>M. T.</given-names></name><name><surname>Yu</surname><given-names>K. K. Q.</given-names></name><etal/></person-group><article-title>IFN-<italic>&#x003b3;</italic>-independent immune markers of <italic>Mycobacterium tuberculosis</italic> exposure</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2019</year><volume>25</volume><issue>6</issue><fpage>977</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0441-3</pub-id><pub-id pub-id-type="other">2-s2.0-85066062891</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>E.</given-names></name><name><surname>L&#x000f3;pez-Varela</surname><given-names>E.</given-names></name><name><surname>Broderick</surname><given-names>C.</given-names></name><name><surname>Seddon</surname><given-names>J. A.</given-names></name></person-group><article-title>Examining the complex relationship between tuberculosis and other infectious diseases in children</article-title><source><italic toggle="yes">Frontiers in Pediatrics</italic></source><year>2019</year><volume>7</volume><issue>233</issue><pub-id pub-id-type="doi">10.3389/fped.2019.00233</pub-id><pub-id pub-id-type="other">2-s2.0-85067515948</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasue</surname><given-names>M.</given-names></name><name><surname>Komiya</surname><given-names>K.</given-names></name><name><surname>Usagawa</surname><given-names>Y.</given-names></name><name><surname>Umeki</surname><given-names>K.</given-names></name><name><surname>Nureki</surname><given-names>S.-i.</given-names></name><name><surname>Ando</surname><given-names>M.</given-names></name></person-group><article-title>Factors associated with false negative interferon-<italic>&#x003b3;</italic> release assay results in patients with tuberculosis: a systematic review with meta-analysis</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2020</year><volume>10</volume><issue>1</issue><fpage>p. 1607</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-58459-9</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y.-S.</given-names></name><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Jeon</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Factors that predict negative results of quantiferon-tb gold in-tube test in patients with culture-confirmed tuberculosis: a multicenter retrospective cohort study</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2015</year><volume>10</volume><issue>6</issue><pub-id pub-id-type="publisher-id">e0129792</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0129792</pub-id><pub-id pub-id-type="other">2-s2.0-84935519792</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China</article-title><source><italic toggle="yes">Clinical Immunology</italic></source><year>2020</year><volume>214</volume><pub-id pub-id-type="publisher-id">108393</pub-id><pub-id pub-id-type="doi">10.1016/j.clim.2020.108393</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>S.</given-names></name><name><surname>Abedi</surname><given-names>A.</given-names></name><name><surname>Balakrishnan</surname><given-names>S.</given-names></name><name><surname>Gholamrezanezhad</surname><given-names>A.</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</article-title><source><italic toggle="yes">American Journal of Roentgenology</italic></source><year>2020</year><volume>215</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">32568579</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study selection process and number of papers included.</p></caption><graphic xlink:href="CRJ2020-1401053.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Known and possible interactions between MTB and coronaviruses.</p></caption><graphic xlink:href="CRJ2020-1401053.002"/></fig></floats-group></article>